Why this chain matters

MacroGenics, Inc. (MGNX) has a mapped ChainSifter graph with 14 supplier links and 14 customer links. That makes it useful for investors trying to understand who benefits when MGNX performs well, and who may be exposed if demand or execution weakens.

The point is not to treat every edge as equal. The useful signal is the shape of the network: named suppliers, named customers, confidence levels, and filing language that shows where business dependence may sit.

Supplier exposure

The supplier side shows the companies and entities most directly tied to MGNX's operating base. Higher-confidence links deserve the first review because they are the relationships most likely to matter when margins, production, procurement, or delivery timelines change.

  • SAGARD-HEALTHCARE-PARTNERS (SAGARD-HEALTHCARE-PARTNERS) - confidence 92%.
  • Incyte Corporation (INCY) - confidence 90%.
  • SYNAFFIX (SYNAFFIX) - confidence 90%.
  • STERLING (STERLING) - confidence 90%.
  • MILLIPORE-SIGMA (MILLIPORE-SIGMA) - confidence 90%.
  • SYMBIOSIS (SYMBIOSIS) - confidence 90%.
  • SIMTRA-BIOPHARMA-SOLUTIONS (SIMTRA-BIOPHARMA-SOLUTIONS) - confidence 90%.
  • Incyte Corporation (INCY) - confidence 90%.

Customer and demand signals

The customer side is where revenue concentration and downstream demand risk usually show up first. If a customer relationship is central to the graph, a change in that customer's spending or inventory cycle can move through the chain quickly.

  • Bora Pharmaceuticals Co., Ltd. (BORAY) - confidence 95%.
  • Bora Pharmaceuticals Co., Ltd. (BORAY) - confidence 95%.
  • INCYTE (INCYTE) - confidence 95%.
  • TERSERA (TERSERA) - confidence 92%.
  • Incyte Corporation (INCY) - confidence 90%.
  • Incyte Corporation (INCY) - confidence 90%.
  • Cardinal Health, Inc. (CAH) - confidence 85%.
  • MCKESSON-SPECIALTY-CARE-DISTRIBUTION-LLC (MCKESSON-SPECIALTY-CARE-DISTRIBUTION-LLC) - confidence 85%.

Filing evidence

ChainSifter is most useful when the map is tied back to source language. These excerpts are the evidence trail behind the graph and should be reviewed before treating a relationship as investable signal.

  • MacroGenics, Inc.: In January 2022, we entered into an agreement with Incyte to provide manufacturing services to produce certain Incyte bulk drug substance over a three-year period.
  • MacroGenics, Inc.: pany will be added to the Aggregate Purchase Price for purposes of calculating the royalty payment cap. Asset Purchase Agreement On May 11, 2026, the Company entered into an Asset Purchase Agreement (Purchase Agreement) with Bora Pharmaceuticals Co., Ltd and B
  • MacroGenics, Inc.: Reciprocal relationship from BORAY graph: Reciprocal relationship from MGNX graph: pany will be added to the Aggregate Purchase Price for purposes of calculating the royalty payment cap. Asset Purchase Agreement On May 11, 2026, the Company entered into an Ass
  • SAGARD-HEALTHCARE-PARTNERS: On May 1, 2026, MacroGenics, Inc. (the 'Company') and an entity affiliated with Sagard Healthcare Partners ('Sagard') entered into a First Amendment to the Purchase and Sale Agreement, dated as of June 9, 2025
  • MacroGenics, Inc.: the Company previously sold to Sagard its right to receive royalties on global net sales of ZYNYZ (retifanlimab-dlwr) under the Company's Global Collaboration and License Agreement dated as of October 24, 2017, as amended (the 'License Agreement'), with Incyte

Who benefits and who is exposed

If MacroGenics, Inc. outperforms, the first-order beneficiaries are the suppliers with high-confidence relationships and the customers that rely on the company's output. If MGNX struggles, the exposed names are the counterparties with fewer alternate channels or relationships that appear repeatedly in the filing trail.

This is the practical use case: map the counterparties, separate confirmed relationships from weak ones, and watch for new filings that change the direction or concentration of exposure.

The most important follow-up is not simply whether a counterparty appears once. It is whether the same relationship persists across filings, appears in risk-factor language, or connects to revenue, procurement, capacity, or delivery obligations. Those are the details that turn a graph edge into investable supply chain intelligence.

What to watch

  • New or removed supplier names in future filings.
  • Customer concentration language that points to revenue dependence.
  • Confidence changes in the ChainSifter graph as new evidence is processed.